[AST] Asterias Biotherapeutics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.


Price: 4.6 Change: 0.25 (5.75%)
Ext. hours: Change: 0 (0%)

chart AST

Refresh chart

Description: Asterias Biotherapeutics, Inc., a development stage biotechnology company, focuses on the development of therapeutic products to treat neurology, oncology, cardiology, metabolic diseases, ophthalmology, orthopedics, and blood and vascular diseases. It is also developing human embryonic stem cell programs, including cell lines and a Phase I clinical trial in patients with acute spinal cord injury; intellectual property related to its autologous cellular immunotherapy program, including a Phase I/II clinical trial of autologous immunotherapy in patients with acute myelogenous leukemia; and non-therapeutic applications of pluripotent stem cells, such as cellular assay products for use in drug development and toxicity screening. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is based in Menlo Park, California.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 3609.52% Sales Growth - Q/Q-26.23% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-20.54% ROE-27.98% ROI
Current Ratio2.62 Quick Ratio Long Term Debt/Equity Debt Ratio0.27
Gross Margin92.53% Operating Margin-946.27% Net Profit Margin-555.54% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities5.36 M Cash From Investing Activities-310 K Cash From Operating Activities-700 K Gross Profit730 K
Net Profit-2.97 M Operating Profit-4.54 M Total Assets52.5 M Total Current Assets27.36 M
Total Current Liabilities10.45 M Total Debt560 K Total Liabilities13.97 M Total Revenue780 K
Technical Data
High 52 week2.25 Low 52 week0.56 Last close0.94 Last change1.24%
RSI50.2 Average true range0.05 Beta1.12 Volume162.01 K
Simple moving average 20 days3.52% Simple moving average 50 days18.78% Simple moving average 200 days-26.14%
Performance Data
Performance Week5.79% Performance Month28.62% Performance Quart-25.87% Performance Half-44.62%
Performance Year-57.2% Performance Year-to-date51.85% Volatility daily7.88% Volatility weekly17.63%
Volatility monthly36.13% Volatility yearly125.14% Relative Volume241% Average Volume195.2 K
New High New Low


2020-05-12 03:08:00 | AusNet Posts Good Fiscal 2020 but Distribution Guidance Disappoints

2019-06-17 03:36:25 | How Financially Strong Is ASTARTA Holding N.V. WSE:AST?

2019-05-14 08:58:34 | One Thing To Remember About The ASTARTA Holding N.V. WSE:AST Share Price

2019-02-14 16:20:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Asterias Biotherapeutics, Inc. – AST

2019-02-08 09:51:02 | What Makes Asterias Biotherapeutics AST a New Buy Stock

2019-01-24 07:00:00 | Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

2019-01-04 08:00:00 | BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase

2018-12-18 17:32:10 | Achillion Reports Positive Interim Data on Factor D Inhibitors

2018-11-27 07:00:00 | Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small Cell Lung Cancer

2018-11-23 08:20:00 | New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-09 17:25:10 | Asterias Biotherapeutics AST Reports Q3 Loss, Tops Revenue Estimates

2018-11-09 16:17:28 | Asterias Biotherapeutics: 3Q Earnings Snapshot

2018-11-09 16:10:00 | Asterias Biotherapeutics Reports Third Quarter Results

2018-11-08 13:49:08 | Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Asterias Biotherapeutics, Inc. AST on Behalf of Stockholders and Encourages AST Investors to Contact the Firm

2018-11-08 12:00:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Asterias Biotherapeutics, Inc.

2018-11-08 11:09:00 | Wolf Popper LLP Investigates the Proposed Acquisition of Asterias Biotherapeutics, Inc. by BioTime, Inc.

2018-11-08 06:35:00 | BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company

2018-11-08 06:30:00 | BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update

2018-11-02 07:00:00 | Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018

2018-10-31 09:45:00 | Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study

2018-10-23 09:32:33 | What Kind Of Shareholders Own Asterias Biotherapeutics Inc NYSEMKT:AST?

2018-10-01 07:00:00 | Asterias Biotherapeutics Announces Facilities and IP License Option Agreements

2018-09-20 07:00:00 | FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program

2018-09-17 15:32:20 | Healthcare Stocks: Is Now The Time To Buy Asterias Biotherapeutics Inc NYSEMKT:AST?

2018-09-12 07:00:00 | Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

2018-09-04 07:00:00 | Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer NSCLC

2018-08-30 08:46:12 | Are Options Traders Betting on a Big Move in Asterias Biotherapeutics AST Stock?

2018-08-29 07:00:00 | Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference

2018-08-09 17:50:09 | Asterias Biotherapeutics AST Reports Q2 Loss, Tops Revenue Estimates

2018-08-09 16:43:30 | Asterias Biotherapeutics: 2Q Earnings Snapshot

2018-08-09 16:10:00 | Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress

2018-08-09 15:00:00 | Asterias Biotherapeutics Inc Class A to Host Earnings Call

2018-07-31 07:00:00 | Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

2018-07-26 07:00:00 | Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018

2018-07-17 08:56:01 | Benzinga Pro's 5 Stocks To Watch Today

2018-07-17 07:00:00 | Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

2018-07-12 07:00:00 | Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke

2018-07-11 11:05:03 | Achillion's 3rd Factor D Inhibitor Enters Clinical Studies

2018-07-11 08:31:12 | VIVUS, Inc. VVUS Soars: Stock Adds 10.1% in Session

2018-07-11 07:00:00 | Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer NSCLC

2018-07-11 05:14:09 | Asterias Biotherapeutics Sees Hammer Chart Pattern: Time to Buy?

2018-07-06 22:11:36 | Asiatravel.com Suspends Trading as Going Concern Risk Flagged

2018-06-26 08:34:29 | Does ASTARTA Holding NV’s WSE:AST -63.13% Earnings Drop Reflect A Longer Term Trend?

2018-06-12 07:00:00 | Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer

2018-06-05 07:00:00 | Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review of AST-OPC1 Clinical Trial in Acute Spinal Cord Injury

2018-05-26 09:41:16 | ASTARTA Holding NV. WSE:AST: Can It Deliver A Superior ROE To The Industry?

2018-05-16 07:00:00 | Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress

2018-05-09 19:54:21 | Asterias Biotherapeutics: 1Q Earnings Snapshot

2018-05-09 16:12:47 | Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress

2018-05-03 16:01:00 | Asterias Biotherapeutics to Report First Quarter 2018 Results on May 9, 2018